In September 2023, Hangzhou Hotide Biotech Co., Ltd., a wholly-owned subsidiary of the company, was registered and established. Hotide Biotech is positioned as a pilot platform for peptide active pharmaceutical ingredients, and committed to serving domestic and foreign customers of generic and innovative drugs. The company has established GMP production lines that comply with FDA and CFDA, and can provide clinical trial products to domestic and foreign customers.